Rocket Lab: The Long View
What the filings say about its story, dilution and cash runway.
Disclosure: one or more of our editors own shares of Rocket Lab (RKLB) as a long-term investment. This page is information, not investment advice.
Sources used most:
- 10-K FY2025, filed Feb 26, 2026
- 10-Q Q3 2026, filed Nov 9, 2026
- Q3 2026 results release, Nov 9, 2026
- 10-Q Q2 2026, filed Aug 10, 2026
1. In one paragraph
Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.
Rocket Lab builds spacecraft and spacecraft parts and launches small satellites. In 2025, space systems brought in $402.8M (67% of revenue) and launch services $199.0M (33%), out of $601.8M total; in the first nine months of 2026, space systems was 77% of $702.2M of revenue (our calculation)1.
- Space systems covers whole satellites, such as a Space Development Agency constellation, and components like solar panels, reaction wheels that control a spacecraft’s orientation, separation systems that release payloads, and laser terminals that transmit data.
- Rocket Lab recognises revenue from many spacecraft programmes as work progresses; other space systems sales are recognised when control passes to the customer.
- Launch services are mainly the Electron rocket, plus HASTE, a suborbital version used for hypersonic tests. Rocket Lab flew 21 missions across Electron and HASTE in 2025. Its larger reusable rocket, Neutron, has not flown yet.
- The company has agreed to buy Iridium Communications, a satellite-phone and data network with $871.7M of 2025 revenue; Rocket Lab expects the deal to close in 2027, after US Federal Communications Commission (FCC) and some foreign approvals (the CEO said mid-2027 in August).
Sources: 10-K FY2025 (segments, launches); 10-Q Q3 2026; Iridium deal release, Jun 29, 2026.
2. Story so far
Last updated Nov 12, 2026. Reflects filings through Nov 9, 2026 and our coverage through Nov 10, 2026.
In short: Rocket Lab’s filings show that satellites and spacecraft parts now supply most of its revenue, a business expanded through acquisitions paid partly in stock, and one unnamed government customer has become its largest; a December 2025 missile-tracking award added an $806M base contract. In 2026 it agreed to buy Iridium and raised $3.9B by selling new shares, enough, it says, to fund the cash part. Rocket Lab delayed its larger Neutron rocket’s first launch twice in 2026 (earlier targets had included 2024 and 2025); it now targets the launch for no earlier than 2027.
| Date | Milestone | Source |
|---|---|---|
| Feb 2024 | Sells $355M of 4.25% convertible notes (debt exchangeable for shares) due 2029; almost all have since converted into stock | 10-Q Q2 2026, note 11 |
| Jan 7, 2025 | CEO Sir Peter Beck’s family trust swaps 50.95M common shares for Series A preferred, which keeps a right to elect a director | 10-K FY2025, note 13 |
| Aug 2025 | Buys GEOST (optical sensors) for $136.2M cash plus 3.06M shares, with up to $50M in additional cash payments tied to GEOST’s revenue targets | 10-Q Q2 2026, note 4 |
| Dec 17, 2025 | ★ Signs an $806M Space Development Agency contract, plus $10M in options, for 18 missile-tracking satellites, with final delivery for launch expected in 2029 | 8-K |
| Jan 21, 2026 | A Neutron first-stage tank ruptures in a pressure test | 8-K |
| Feb 26, 2026 | 2025 results: revenue $601.8M (+38%); Neutron’s first launch retargeted to Q4 2026 | Release |
| Mar 30, 2026 | Beck agrees to cut his salary to $1 (or the New Zealand statutory minimum) and cancels all his unvested restricted stock units (rights to receive shares when vesting conditions are met) | 8-K |
| Apr 14, 2026 | Closes Mynaric (laser terminals, Germany), paid in 2.28M shares | 8-K |
| Jun 28, 2026 | ★ Agrees to buy Iridium: $27 cash plus Rocket Lab stock per Iridium share; deal enterprise value (equity value plus debt, less cash) approximately $8.0B | 8-K |
| Aug 10, 2026 | Q2 revenue a record $234.1M; backlog (contracted revenue not yet recognised) $2.36B. Rocket Lab also disclosed a $397M contract, including options, to deliver Flatellite spacecraft launching on Neutron for a US Space Force airborne-threat tracking programme | Release |
| Sep 15, 2026 | ★ Completes a share sale raising $1.944B gross (29.3M shares); Rocket Lab said the proceeds, available cash and lender consent to keep Iridium’s existing $1.775B term loan fully financed the deal, so the $3.6B bridge commitment was cancelled. | 8-K |
| Sep 24, 2026 | Iridium shareholders approve the deal | Iridium Q3 release |
| Oct 14, 2026 | ★ Neutron’s first launch moves into 2027 | 8-K |
| Oct 20, 2026 | Iridium reports $2.2B of gross debt at Sep 30, following its July acquisition of Aireon, an aircraft-surveillance business | Iridium Q3 release |
| Oct 26, 2026 | Start of our coverage: Why Rocket Lab stock is down so much | WhyMyStockMoved |
| Nov 9, 2026 | Q3 revenue a record $267.8M; backlog $3.57B (+52% in the quarter), with more than $515M of new Neutron contracts at a base price of $70M for several missions; the 10-Q says voids found in October in a fuel-tank dome require a replacement, and the release targets Neutron’s first launch for “no earlier than 2027” | Release, 10-Q |
| Nov 10, 2026 | Our Q3 review | WhyMyStockMoved |
3. Latest quarter: did the story change?
Last updated Nov 12, 2026. Reflects Q3 2026 (10-Q filed Nov 9, 2026) and the Nov 9 earnings call.
Bottom line: Q3 revenue beat the top of Rocket Lab’s own range and backlog rose 52% in the quarter, but Neutron’s first launch moved into 2027 and the net loss grew to $79.7M, including $27.3M of costs from ending an unused Iridium loan commitment and $21.3M of transaction costs.
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Revenue | Q2 $234.1M → Q3 $267.8M (space systems $189.5M → $214.8M; launch $44.6M → $53.1M) | Q3 guide $250–265M (Aug 10) → delivered $267.8M; Q4 guide $270–290M (Nov 9) | Better |
| Backlog | Jun 30 $2.36B → Sep 30 $3.57B (launch $0.94B → $1.85B); about 33% expected within 12 months (was 45%) | Part of the year’s increase was acquired (10-Q) | Better |
| Gross margin (revenue less cost of revenue, divided by revenue) under US accounting rules (GAAP) | Q2 36.1% → Q3 33.6% | Q3 guide 29–31% (Aug 10) → above it; Q4 guide 34–36% (Nov 9) | Better |
| Adjusted EBITDA (the company’s earnings measure excluding interest, tax, depreciation, amortisation, stock pay and certain other items) | Q2 −$8.8M → Q3 −$18.0M | Q3 guide −$17M to −$23M (Aug 10) → within it; Q4 guide −$14M to −$20M (Nov 9) | Worse |
| Neutron first launch | Q4 2026 target → no earlier than 2027 | Q4 2026 (Feb 26) → expected in 2027 (Oct 14) → “no earlier than 2027” (Nov 9 release), after voids were found in a composite fuel-tank dome; Rocket Lab will give a more specific date after first-stage tests (10-Q) | Worse |
Sources: Q2 release, Q3 release, 10-Q Q3 2026, Neutron release, Oct 14.
On the Nov 9 call, chief executive Peter Beck declined to give a month or quarter for Neutron’s first launch (“I think if I provide a date, clearly, I’ve been wrong”), and chief financial officer Adam Spice tied the margin dip mainly to the first full quarter of Mynaric and the absence of Q2’s tariff refunds (Reported: Investing.com transcript, not checked against the company’s recording).
Unresolved questions: the new Neutron date; the remaining Iridium approvals; whether the Q4 margin recovery Rocket Lab guided arrives.
4. Buybacks vs real dilution (5 years)
Last updated Nov 12, 2026. Reflects the equity statements in the 10-K FY2023, 10-K FY2025 and 10-Q Q3 2026.
Dilution in one line: shares outstanding (common plus preferred) rose 51% from Dec 31, 2021 to Sep 30, 2026, about 9.1% a year compounded. If you owned 1% of Rocket Lab at the end of 2021, you would have owned about 0.66% on Sep 30, 2026 without buying more (our calculation)2. Paying for Iridium partly in shares would add more. None of the new shares were offset by buybacks. Our scale: High (over 3% a year).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2021 Part year
Shares outstanding at period end (all classes): 450.2M on Dec 31, 2021, 680.1M on Sep 30, 2026, +51.1% (our calculation). A bar below zero means the count fell (net buybacks).
Common plus Series A preferred (issued to Sir Peter Beck's trust in exchange for common shares in 2025), as the author counts them.
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| 9M 2026 (Sep 30, 2026) | 680.1M | +15.4% | — | — | — |
| FY2025 (Dec 31, 2025) | 589.5M | +16.9% | — | $71M | 12% |
| FY2024 (Dec 31, 2024) | 504.5M | +3.2% | — | $57M | 13% |
| FY2023 (Dec 31, 2023) | 488.9M | +2.9% | — | $53M | 22% |
| FY2022 (Dec 31, 2022) | 475.4M | +5.6% | — | $56M | 26% |
| FY2021 (Dec 31, 2021) | 450.2M | — | — | $33M | 52% |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
How we calculated this
Rocket Lab has bought back no stock since 2022. The largest cumulative source was share sales (including the collateral shares), followed by note conversions and equity plans. Counts below are common shares issued; from 2025 these include the 40.95M–45.95M shares held in treasury against Beck’s preferred, so they equal common plus preferred.
| Bridge (millions of shares) | 2022 | 2023 | 2024 | 2025 | 9M 2026 | Total |
|---|---|---|---|---|---|---|
| Start of period | 450.2 | 475.4 | 488.9 | 504.5 | 589.5 | 450.2 |
| Stock pay and options (equity plans) | 18.2 | 12.9 | 14.8 | 12.3 | 6.9 | 65.1 |
| Share sales for cash (at-the-market sales, new shares sold into the market through brokers, including 7.45M collateral shares for forward sales) | – | – | – | 30.8 | 51.3 | 82.1 |
| Convertible notes converted | – | – | – | 38.9 | 30.1 | 69.0 |
| Acquisitions | 2.4 | 0.7 | 0.2 | 3.1 | 2.3 | 8.6 |
| Warrants (rights to buy shares at a set price) exercised | 4.6 | – | 0.5 | – | – | 5.1 |
| Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| End of period | 475.4 | 488.9 | 504.5 | 589.5 | 680.1 | 680.1 |
- The 9M 2026 share-sale line includes 7.45M shares issued in September as collateral for collared forward sales; they count as issued and outstanding under US accounting rules, but the cover of the 10-Q excludes them from its count of 632.0M common shares at Nov 4, 2026 (10-Q). Totals are on unrounded filing figures3.
- Reported basic and diluted weighted-average shares were 466.2M in 2022 and 629.3M in the first nine months of 2026 (10-K FY2023, 10-Q). These loss-per-share denominators exclude securities whose inclusion would reduce the reported loss per share.
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2022 | — | — | — | — | — | — | 10-K FY2023 equity statement |
| 2023 | — | — | — | — | — | — | 10-K FY2023 |
| 2024 | — | — | — | — | — | — | 10-K FY2025 equity statement |
| 2025 | — | — | — | 30.8M | $37.20 (our calculation) | $1,146.1M | 10-K FY2025, note 13: 15.14M shares for $396.6M (March 2025 programme) and 15.66M for $749.4M (September 2025 programme), gross |
| 2026 to Sep 30 | — | — | — | 43.8M | $79.27 (our calculation) | $3,474.0M | 10-Q Q3 2026, note 12: 6.73M shares for $474.0M (March 2026 programme), 7.78M for $1,055.6M (May 2026) and 29.31M for $1,944.4M (August 2026), gross. Separately, $437.9M received early on the collared forward sales (7.45M collateral shares) |
Rocket Lab sold shares for cash in 2025 and 2026 and bought none back, so the prices received are the only prices to compare.
- Prices are per share and split-adjusted (Rocket Lab has had no stock split since listing in 2021).
- Raised is gross proceeds before commissions and costs, and average price is our calculation4.
- Rocket Lab made no buybacks in the period. Employee shares sold to cover taxes are not buybacks; the company sells them in the market on employees’ behalf (10-Q, cash flow statement).
- Not counted as sales for cash in the table: warrant exercises in 2022 and 2024 (5.1M shares); shares issued for acquisitions and note conversions; and the collared forward sales (forward share sales with contractual minimum and maximum proceeds) under the March 2026 sales agreement. In September Rocket Lab asked for early payment on all of them, received $437.9M (the discounted value of the minimum proceeds) and issued the 7.45M shares as collateral; up to about $168M more may come at settlement in April 2028.
- For reference, Nasdaq’s historical quotes show a closing price of $64.07 on Nov 12, 2026.
Further possible sources of new shares or cash are not in the table above: the rest of the forward-sale proceeds in 2028, the shares to be issued for Iridium, and capped calls (options bought in 2024 to offset conversion dilution), which could pay up to $201.9M at expiries from Dec 1, 2028 to Jan 30, 2029, depending on the share price.
Forward sales and Iridium share issuance
- The collared forward sales covering 7.45M shares stay outstanding until their April 2028 maturities. Rocket Lab has already received $437.9M; at settlement it could receive up to about $168M more, depending on its share price against an average floor of $63.61 and cap of $86.11 (10-Q, note 12).
- Using the Iridium share count in the merger proxy (105.956M), the deal would issue about 42.4M Rocket Lab shares for Iridium’s common shares at the maximum exchange ratio of 0.40 (our calculation)5.
- That ratio applies when Rocket Lab’s ten-trading-day volume-weighted average price, measured shortly before closing, is $67.50 or less. The figure excludes Iridium equity awards and later share-count changes (proxy).
| Stock-based pay | 2022 | 2023 | 2024 | 2025 | 9M 2026 |
|---|---|---|---|---|---|
| $M | 55.6 | 53.5 | 56.8 | 71.1 | 66.0 |
| % of revenue (our calculation)6 | 26% | 22% | 13% | 12% | 9% |
The 9M 2026 figure includes an $11.2M one-off charge from Beck’s cancelled awards.
5. Profit vs cash (latest FY and TTM)
Last updated Nov 12, 2026. Reflects the 10-K FY2025, the 10-Q Q3 2026 and the company’s adjusted EBITDA reconciliations.
Rocket Lab reports net and adjusted EBITDA losses. Free cash flow (operating cash flow minus capital spending) was also negative in both periods shown. Free cash outflow exceeded the net loss in both periods shown; capital spending and cash tied up in operations contributed to the gap.
| $M | FY2025 | Trailing twelve months (TTM) to Sep 30, 2026 (our calculation)7 |
|---|---|---|
| Net loss | −198.2 | −226.9 |
| Adjusted EBITDA (the company’s own earnings measure before interest, tax, depreciation, amortisation, stock pay and certain other items) | −101.2 | −56.0 |
| Operating cash flow | −165.5 | −191.8 |
| Capital spending | −156.3 | −133.8 |
| Free cash flow (our calculation)8 | −321.8 | −325.6 |
Helps future profit or cash:
- Working capital took $58.8M of cash in 2025, and in the first nine months of 2026 receivables, contract assets and inventory used $68.5M, $60.8M and $83.7M: cash tied up that can be released as customers pay and stock is sold, subject to collection and write-downs.
- Customer advances (contract liabilities) provided $144.5M in the first nine months of 2026, $65.7M of it in Q3, when operating cash flow turned positive at $7.2M: cash received before revenue is recognised, so recognising it later brings no further cash receipt.
- Interest income ($25.5M in 2025; $55.3M in the first nine months of 2026, on the larger cash balance) reduces the net loss and arrives as cash, but is taken out of adjusted EBITDA. Most of that cash is earmarked for Iridium.
Hurts future profit or cash:
- Capital spending more than doubled in 2025, to $156.3M from $67.1M: cash out now, with the cost reaching profit gradually through depreciation.
- Depreciation and amortisation ($43.9M in 2025) lowers reported profit each year but is not a cash cost; it is added back in adjusted EBITDA.
- Stock-based compensation ($71.1M in 2025) is a non-cash expense that dilutes ownership; the company adds it back when calculating adjusted EBITDA.
One-off / no lasting effect:
- A $30.7M deferred-tax benefit reduced the 2025 accounting loss without generating operating cash.
- In Q3 2026 Rocket Lab paid $27.3M of financing costs and fees on ending the unused Iridium bridge-loan commitment and booked $21.3M of transaction costs (10-Q).
The raw reconciling items
From the filings:
- Stock-based compensation reduced 2025 net income by $71.1M. The company adds this non-cash expense back when calculating adjusted EBITDA.
- Depreciation and amortisation ($43.9M in 2025) is added back too.
- Interest income ($25.5M in 2025) reduces the net loss but is taken out of adjusted EBITDA.
- Working capital took cash: $58.8M in 2025 (10-K MD&A). In the first nine months of 2026, changes in receivables, contract assets and inventory used $68.5M, $60.8M and $83.7M of operating cash; changes in contract liabilities (mostly customer advances) provided $144.5M.
- Capex more than doubled in 2025, to $156.3M from $67.1M.
- A $30.7M deferred-tax benefit also reduced the 2025 accounting loss without generating operating cash.
Funding: how long without new money? Cash-burning: Sep 30 cash, cash equivalents and marketable securities of about $4.70B covered about 14.4 years of trailing-12-month free cash outflow of $325.6M (our calculation)9, but most of it is earmarked for Iridium. With Iridium’s closing cash, the cash path below stays positive until Q3 2030, when the retained Iridium term loan (about $1.7B) matures; without refinancing, cash would fall below zero then.
Funding details
- As of Sep 30, 2026, the latest filed balance sheet. The 14.4 years is a historical comparison rather than a forecast, and it is based on past cash flow; spending plans can change it.
- The share sales are complete: $3,474.0M gross from at-the-market sales in the first nine months of 2026, plus $437.9M received early on the collared forward sales; Rocket Lab says the deal is “now fully financed” and it does not need to raise more to close it (Nov 9 call; Reported: Investing.com transcript).
- Rocket Lab expects to need over $3.0B of cash to complete the Iridium deal (10-Q). Using the disclosed acquisition components (about $3,198.9M before fees), the illustrative comparison is about 4.6 years (our calculation)10, before the Iridium term-loan principal, revolver repayment and term-loan maturity that the cash path below adds.
Extends the runway:
- Up to about $168M more from the collared forward sales at their April 2028 settlement, depending on the share price; not in the cash path (financing table below).
- The Sep 30 10-Q disclosed no undrawn credit lines. On Nov 9, 2026, the Office of Strategic Capital announced a $150M conditional loan commitment to support Neutron capacity; financial close requires further financial, legal, technical and other conditions, so no receipt is included in the cash path (Office of Strategic Capital release).
- Capped calls (options Rocket Lab bought in 2024 to offset dilution from its convertible notes) could pay up to about $201.9M at expiries from Dec 1, 2028 to Jan 30, 2029, depending on the share price; not in the cash path (10-Q).
Shortens the runway:
- About $3,198.9M of Iridium closing cash (in the cash path, placed in Q2 2027), then about $18.3M a year of principal on Iridium’s retained term loan (about $4.6M a quarter) until the loan matures in September 2030 (Iridium Q3 2026 10-Q, Note 5). Deal costs already paid before Sep 30, including the $27.3M for ending the bridge commitment and the share-sale costs, are in the starting cash.
- At Sep 30, Rocket Lab had $1.3M of convertible-note principal due Feb 1, 2029, plus $1.7M of other borrowings classified as non-current (10-Q). The company intends to settle the notes in stock, so they count as $0 cash.
- After closing, Rocket Lab USA, its main operating subsidiary, will guarantee Iridium’s roughly $1.8B term loan (10-Q). Iridium reported $2.2B of gross debt at Sep 30, including a $183.4M interest-free seller loan maturing one year after its Jul 2, 2026 Aireon closing, a $154.7M Aireon credit facility due Oct 10, 2028, and $50M drawn on its revolving credit facility, which matures September 2028 and is repaid in the cash path (Iridium Q3 release).
- The GEOST earn-out: up to $50M in cash, contingent on GEOST’s 2026–27 revenue; timing not disclosed, so not in the cash path.
Conditional:
- The Motiv earn-out: up to $20M, payable in stock, so $0 cash.
Cash path (our calculation; an illustration, not a forecast):
At the past rate and with the closing assumptions above, cash would fall below zero in Q3 2030 unless the Iridium term loan is refinanced; Rocket Lab says its existing cash, marketable securities and customer payments will cover working capital and capital spending for at least the next twelve months (10-Q).
Illustration, not a forecast.
- 1 · Q2 2027 · Iridium closing cash −$3.20B
- 2 · Q3 2027 · Iridium term-loan principal −$5M
- 3 · Q4 2027 · Iridium term-loan principal −$5M
- 4 · Q1 2028 · Iridium term-loan principal −$5M
- 5 · Q2 2028 · Iridium term-loan principal −$5M
- 6 · Q3 2028 · Iridium term-loan principal and repayment −$55M
- 7 · Q4 2028 · Iridium term-loan principal −$5M
- 8 · Q1 2029 · Iridium term-loan principal −$5M
- 9 · Q2 2029 · Iridium term-loan principal −$5M
- 10 · Q3 2029 · Iridium term-loan principal −$5M
- 11 · Q4 2029 · Iridium term-loan principal −$5M
- 12 · Q1 2030 · Iridium term-loan principal −$5M
- 13 · Q2 2030 · Iridium term-loan principal −$5M
- 14 · Q3 2030 · The retained Iridium term loan matures −$1.71B
- 15 · Cash if drawn: −$1.45B at Q3 2030
Ending cash (cash, equivalents and marketable securities) Known item Raising window (under a year of usual spending left) Would need new money If committed financing is drawn
| Quarter | Starting cash | Usual spending | Known items | Ending cash | Sources / notes |
|---|---|---|---|---|---|
| Q4 2026 | +4,703.8 | −81.4 | 0.0 | +4,622.4 | |
| Q1 2027 | +4,622.4 | −81.4 | 0.0 | +4,541.0 | |
| Q2 2027 | +4,541.0 | −81.4 | −3,203.5 | +1,256.1 | Iridium closing cash, approximately $3,198.9M ($2,860.8M common-share cash consideration plus $338.1M to pay off Aireon debt, using the financing amounts disclosed for Iridium’s Jul 2, 2026 Aireon purchase, held constant; our calculation)11, and −$4.6M of Iridium term-loan principal (about $18.3M a year; Iridium Q3 2026 10-Q, Note 5). Both the amount and the quarter are assumptions: the Aireon payoff may differ by closing, including any prepayment premium, and the timing depends on approvals; Rocket Lab expects to close in 2027 (outside date Jun 28, 2027, extendable). Rocket Lab’s own figure is “over $3.0 billion” including fees and expenses (10-Q) |
| Q3 2027 | +1,256.1 | −81.4 | −4.6 | +1,170.1 | Iridium term-loan principal |
| Q4 2027 | +1,170.1 | −81.4 | −4.6 | +1,084.1 | Iridium term-loan principal |
| Q1 2028 | +1,084.1 | −81.4 | −4.6 | +998.1 | Iridium term-loan principal |
| Q2 2028 | +998.1 | −81.4 | −4.6 | +912.1 | Iridium term-loan principal |
| Q3 2028 | +912.1 | −81.4 | −54.6 | +776.1 | Iridium term-loan principal (−$4.6M) and repayment of the $50.0M drawn on Iridium’s revolving credit facility, which matures September 2028 (Iridium Q3 2026 10-Q, Note 5) |
| Q4 2028 | +776.1 | −81.4 | −4.6 | +690.1 | Iridium term-loan principal |
| Q1 2029 | +690.1 | −81.4 | −4.6 | +604.1 | Iridium term-loan principal |
| Q2 2029 | +604.1 | −81.4 | −4.6 | +518.1 | Iridium term-loan principal |
| Q3 2029 | +518.1 | −81.4 | −4.6 | +432.1 | Iridium term-loan principal |
| Q4 2029 | +432.1 | −81.4 | −4.6 | +346.1 | Iridium term-loan principal |
| Q1 2030 | +346.1 | −81.4 | −4.6 | +260.1 | Iridium term-loan principal. Less than a year of usual spending left. |
| Q2 2030 | +260.1 | −81.4 | −4.6 | +174.1 | Iridium term-loan principal. Less than a year of usual spending left. |
| Q3 2030 | +174.1 | −81.4 | −1,706.0 | −1,613.3 | The retained Iridium term loan matures in September 2030: about $1,706.0M of remaining principal (our calculation)12, assuming no refinancing (Iridium Q3 2026 10-Q, Note 5) |
Amounts in $M.
Financing that could extend the runway (committed or contracted, not in the cash path above):
| Quarter | Financing that could extend the runway | Amount | Conditions | Source |
|---|---|---|---|---|
| Q2 2028 | Settlement of the collared forward sales (7.45M shares; April 2028 maturities) | +168.0 | Upper bound (“up to approximately $168M”); it could be zero. $437.9M was already received in September; any further amount depends on the share price against the $63.61 floor and $86.11 cap | 10-Q Q3 2026, note 12 |
This money is not in the cash path above. Even the full $168M would not change the first negative quarter, Q3 2030, when the Iridium term loan matures (our calculation)13.
At the past rate and with the closing assumptions above, cash would fall below zero in Q3 2030 unless the Iridium term loan is refinanced; Rocket Lab says its existing cash, marketable securities and customer payments will cover working capital and capital spending for at least the next twelve months (10-Q). Companies usually refinance or raise money well before that; quarters with less than a year of usual spending left are shaded.
What the cash path counts:
- Usual spending: about −$81.4M a quarter, held flat.
- Known items: about −$3.2B of Iridium closing cash placed in Q2 2027 (closing expected in 2027; outside date Jun 28, 2027), about −$4.6M a quarter of Iridium term-loan principal from that quarter (our timing assumption), the −$50.0M Iridium revolver repayment in Q3 2028 and the term loan’s remaining principal at its September 2030 maturity.
- The $1.3M of convertible notes due Feb 1, 2029 count as $0 cash, because the company intends to settle them in stock.
How we calculated this
Usual spending is trailing-12-month free cash flow (−$325.6M, Q4 2025–Q3 2026) ÷ 4 ≈ −$81.4M a quarter, held flat. Starting cash is cash, cash equivalents and marketable securities at Sep 30, 2026 ($4,703.8M: $4,447.7M cash and equivalents plus $256.2M of marketable debt securities). Known items are disclosed amounts only; the Iridium payment is built from disclosed components, and its quarter, the Aireon payoff amount and the start of Iridium’s term-loan principal payments are our assumptions within the expected 2027 closing. Not included:
- Closing transaction costs: the merger proxy estimated $229.2M using June 30, 2026 information (proxy, Note 5). How much is still payable after Sep 30 has not been disclosed, so it is left out; the run-out would be earlier if those costs are paid in cash.
- The run-out would also be earlier if the acquisition cash requirement is higher or other omitted cash outflows occur.
- Interest income: the past year’s free cash flow includes interest earned on a growing cash balance ($28.6M in Q3 2026 alone); after Iridium closes, that income falls with the balance, so the path may understate spending after Q2 2027.
- The GEOST earnout: up to $50M in cash, contingent on GEOST’s 2026–27 revenue; timing not disclosed (10-Q).
- The Motiv earnout: up to $20M, payable in stock, so $0 cash.
- Lease payments, under the no-double-counting rule: operating-lease payments and finance-lease interest are already in operating cash flow; finance-lease principal is very small ($0.2M in the first nine months of 2026).
- Capital spending is inside usual spending: trailing-12-month capex was $133.8M, against $156.3M in 2025. The company has not quantified a capex plan for 2026–27; the Neutron programme and the Iridium satellite fleet could change it.
- The collared forward settlement: 0 to about $168M in April 2028 (financing table above, not in the path).
- Iridium’s own cash flow after closing.
Sources: Q4 2025 release and Q3 2026 release, adjusted EBITDA reconciliations; 10-Q Q3 2026.
6. Customer and contract exposure
Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q Q3 2026.
Revenue concentration in one unnamed government customer has risen from under 10% of revenue in 2023 to 42% in the first nine months of 2026, while backlog is now split almost evenly between space systems and launch.
Chart source14.
| Customers at 10% or more of revenue | 2023 | 2024 | 2025 | 9M 2026 |
|---|---|---|---|---|
| “Government customer” (not named in the filings) | <10% | 11% | 28% | 42% |
| MDA Corporation (named) | 13% | 23% | <10% | <10% |
| Northrop Grumman Space Systems (named) | 13% | <10% | <10% | <10% |
Contract and exposure details
- Rocket Lab disclosed an $806M base contract for 18 Space Development Agency satellites, rising to $816M if all options are exercised. Either side can end it for convenience (8-K).
- Rocket Lab says some deliveries under the MDA contract (2022, 17 spacecraft buses, the platforms that carry and support satellite payloads) are delayed. MDA may claim liquidated damages (contractual compensation for delivery delays), while Rocket Lab may claim compensation from suppliers that contributed to the delays; the net amount remains uncertain. The 10-Q still describes the delays; at Sep 30, 2026 the customers above 10% of receivables were Synspective (11%) and Muon Space (11%).
- Rocket Lab has signed loan agreements with four commercial launch customers to fund milestone payments, at 9.1–12.6% interest after launch. One loan was repaid; $41.0M was outstanding at Sep 30, 2026 (Jun 30: $32.2M; our calculation)15.
- Backlog stood at $3.57B at Sep 30, 2026 ($1.72B space systems, $1.85B launch), of which about 33% is expected to be recognised within 12 months. Neutron accounts for 16 booked launches; Rocket Lab said on Nov 9 that the next open Neutron slots are in the 2030s (Reported: Investing.com transcript). Launch and spacecraft contracts typically allow the customer to cancel on notice with a fee (10-Q).
- If the deal closes, Iridium brings its own government exposure: Iridium said the US government was its largest single customer in Q3 2026, accounting for 15% of service revenue and nearly all of its engineering and support business. Its main government contract, Enhanced Mobile Satellite Services (EMSS), has been extended to March 2027, and Iridium expects to renew it in 2027 (Iridium Q3 release).
7. What to watch
Last updated Nov 12, 2026. Reflects the 10-Q for Q3 2026, the Q3 release and call, and company announcements through Nov 9, 2026.
| Date | Item | Source |
|---|---|---|
| ~Q1 2027 | End of Neutron first-stage work: a replacement forward dome, tank assembly, then pressure and cold-fuel tests, after which Rocket Lab expects to give a more specific launch date. In October Beck said the work could finish in Q1 2027 if all goes to plan (Space.com); on Nov 9 he declined to give a month or quarter (Reported) | 10-Q Q3 2026; Space.com, Oct 16; call transcript |
| Early 2027 (date not announced) | Q4 and full-year 2026 results; the Q4 guide is revenue of $270–290M, GAAP gross margin of 34–36% and an adjusted EBITDA loss of $14–20M | Q3 release |
| Mar 2027 | Iridium’s EMSS contract extension ends; renewal expected in 2027 | Iridium Q3 release |
| 2027 (outside date Jun 28, 2027, extendable to Sep 28 and Dec 28, 2027) | Iridium closing, after FCC and some foreign approvals; Iridium shareholders approved the deal on Sep 24 and the US antitrust waiting period has expired | 10-Q Q3 2026; 8-K, Jun 29 |
| Apr 2028 | Settlement of the collared forward sales (7.45M shares): $437.9M already received; up to about $168M more | 10-Q Q3 2026 |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | $53.82 (Oct 26) | $32.2BIncluding the Series A preferred stock: $34.4B | $29.8B | 41.9× | 38.8× | n/m | n/m | +53% | −48% | $2.4B | 12 months to Jun 30, 2026 |
| Nov 12, 2026 | $64.07 (Nov 12) | $41.0BIncluding the Series A preferred stock: $43.6B | $36.3B | 46.5× | 41.1× | n/m | n/m | +59% | −37% | $4.7B | 12 months to Sep 30, 2026 |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026 row: Corrected Oct 31, 2026: market value now uses common shares outstanding (598.4 million on the 10-Q cover page, Aug 5, 2026), our standard basis, instead of 639.1 million shares including the Series A preferred stock; market value $32.2B (was $34.4B), with enterprise value and multiples recalculated. Price and date unchanged. Updated Nov 12, 2026: cash and investments now include $85.4M of long-term marketable securities (now $2.39B, was $2.30B), and debt includes $16.2M of borrowings and finance leases (now $29.3M, was $13.1M); net cash is $2.36B (was $2.29B) and enterprise value $29.84B (was $29.91B); EV/sales 38.8× (was 38.9×). Price, date and the other ratios are unchanged. Nov 12, 2026 price: Nasdaq historical close.
Notes and calculations
-
Space systems $540.9M ÷ total $702.2M = 77.0% (10-Q Q3 2026, MD&A). ↩
-
Remaining ownership = 1% × 450.2 ÷ 680.1 ≈ 0.66%; growth = (680.1 ÷ 450.2 − 1) × 100 ≈ 51%; annual growth = [(680.1 ÷ 450.2)^(1 ÷ 4.75) − 1] × 100 ≈ 9.1%. ↩
-
9M 2026: 589,525,802 issued at Dec 31, 2025 + 6,925,396 equity plans + 51,273,828 at-the-market and collateral shares + 30,112,935 note conversions + 2,277,002 for Mynaric = 680,114,963 (10-Q Q3 2026, equity statement). ↩
-
Gross proceeds ÷ shares sold. ↩
-
105.956M × 0.40. ↩
-
Stock-based compensation ÷ revenue × 100. ↩
-
FY2025 − 9M 2025 + 9M 2026. Net loss −$198.209M + $145.287M − $173.957M = −$226.879M; adjusted EBITDA −$101.190M + $83.821M − $38.631M = −$56.000M; operating cash flow −$165.521M + $100.990M − $127.254M = −$191.785M; capital spending −$156.285M + $106.631M − $84.185M = −$133.839M. ↩
-
Operating cash flow plus the capital-spending outflow shown above, on unrounded filing figures: −$191.785M − $133.839M = −$325.624M. Displayed figures may not sum because of rounding. ↩
-
$4,703.8M ÷ $325.6M = 14.4 years. ↩
-
($4,703.8M − $3,198.9M) ÷ $325.6M = 4.6 years. ↩
-
105.956272M Iridium common shares × $27 = $2,860.8M cash consideration; plus $338.1M of Aireon debt ($183.4M seller loan + $154.7M Aireon credit facility, the acquisition financing amounts disclosed for Iridium’s Jul 2, 2026 Aireon purchase, held constant for this illustration; the actual closing repayment will reflect amortisation and any applicable premium). Basis for the payoff: the merger proxy says “the parties intend to terminate and payoff the commitments and outstanding indebtedness under each of the Aireon Credit Agreement and the Aireon Seller Loan Agreement” (Termination of Iridium’s Existing Debt, p. 98), without stating amounts or timing; Rocket Lab’s Q3 10-Q says the transaction is “expected to require over $3.0 billion in cash related to share consideration payments, repayment of certain outstanding Iridium acquisition indebtedness and payment of transaction fees and expenses”. Two assumptions: the amount is held at the disclosed acquisition financing amounts, and the actual payoff may differ by closing (the Aireon facility amortises before then, and a prepayment premium may apply); and the timing is the assumed closing quarter, which depends on approvals. Without the payoff, ending cash at Q2 2030 would be about $512.2M, and cash would still fall below zero in Q3 2030 at the term-loan maturity (our calculation). ↩
-
Remaining principal at maturity ≈ $1,775M term loan (Sep 15, 2026, 8-K and Q3 10-Q: “approximately $1.8 billion”) − 15 quarterly payments of about $4.6M (Q4 2026 to Q2 2030) = about $1,706.0M; Iridium makes the payments before closing. ↩
-
Q2 2028 ending cash 912.1 + 168.0 = 1,080.1; carried forward at the same quarterly items, Q2 2030 ending cash would be 342.1, and the Q3 2030 maturity (about −1,706.0) would still take cash below zero (342.1 − 81.4 − 1,706.0 = −1,445.3). ↩
-
Accessed Nov 12, 2026: 10-Q Q3 2026 (customer concentration, backlog); earlier years from 10-K FY2025 · 10-Q Q2 2026 (customer concentration, backlog). Customers below 10% are not charted. ↩
-
$11.550M in prepaids and other current assets + $29.400M in other non-current assets = $40.950M (10-Q Q3 2026, note 3). ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About Rocket Lab: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)